Uncategorized

BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta

Published

on

BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label.

The FDA greenlit …

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version